Alibaba Stock Keeps Spiraling Down: Could It Bounce?

FX Empire

Preview: What to Expect From Medtronic’s Earnings on Tuesday

“Medtronic is well aligned with our 2021 pro-recovery thesis, and we see sustainable 5%+ organic growth driven by the company’s 5% WAMGR and supported by pipeline product launches and tuck-in M&A contributions (Micra AV, EV-ICD, EPIX, RDN, Zeus/Synergy, 780G, InPen, DTM, Interstim Micro, and the soft tisssue robot),” noted Cecilia Furlong, equity analyst at Morgan Stanley.